Gold prices steady ahead of Fed decision; weekly weakness noted
IRVINE, CA— Masimo Corp (NASDAQ:MASI), a medical technology company with a market capitalization of $9 billion and a notable 49% stock price surge over the past six months, saw its Chief Operating Officer Muhsin Bilal recently execute significant stock transactions, according to a recent SEC filing. According to InvestingPro analysis, the stock currently trades above its Fair Value, with 7 analysts recently revising their earnings expectations upward. On March 10, Bilal sold shares totaling approximately $5.02 million. The sales were conducted at prices ranging from $163.28 to $171.76 per share.
In addition to the sales, Bilal exercised options to acquire 30,000 shares of common stock at a price of $37.84 per share, amounting to a total of $1.14 million. Following these transactions, Bilal holds 24,172 shares of Masimo stock.
These transactions were part of a pre-arranged trading plan intended to comply with Rule 10b5-1.
In other recent news, Masimo Corporation reported strong financial results for the fourth quarter of 2024, surpassing earnings expectations with an EPS of $1.80, well above the forecasted $1.42. The company’s revenue also exceeded projections, reaching $600.7 million compared to the anticipated $591.64 million. This performance is part of Masimo’s broader strategy to focus on its core healthcare business, which has been highlighted by a 46% increase in operating profit. Additionally, BTIG analyst Sean Lavin raised the price target for Masimo shares to $206, maintaining a Buy rating due to the company’s effective cost structure optimization and margin expansion efforts.
Masimo has updated its FY25 Healthcare operating margin guidance to a range of 27.5-28.0%, marking a significant year-over-year expansion. The company has also reaffirmed its 2025 guidance of $1.50 billion to $1.53 billion in healthcare revenue, reflecting an 8-11% year-over-year increase. This positive outlook is further supported by Masimo’s record year in new contracts, amounting to $432 million, which has contributed to its market share gains.
Masimo’s adjusted EPS guidance for 2025 has been raised to $5.10-$5.40, surpassing the consensus estimate of $4.69. The company’s healthcare business continues to show robust performance, with Consumables and Services revenue increasing by 15%. New CEO Katie Ziman is focusing on reinforcing Masimo’s leadership in the healthcare market, emphasizing continuous patient monitoring and expanding the company’s core business.
This article was generated with the support of AI and reviewed by an editor. For more information see our T&C.